Modification of coronary artery disease using antithrombotic therapy.
I review some of the literature concerning antithrombotic therapy in coronary artery disease. The beneficial effects shown are compatible with the unitary hypothesis of thrombosis as a fundamental of cardiovascular risk. The therapeutic approach is limited by the haemorrhagic risk produced by most antithrombotic therapies. A search should therefore be made for antithrombotic therapies without this risk, of which serotonin antagonism appears to be the most promising at present.
Drake-Holland
A J
AJ
Academic Unit of Cardiovascular Medicine, Charing Cross and Westminister Medical School, London, UK.
D000818:Animals; D003327:Coronary Disease / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D012307:Risk Factors
D005343:Fibrinolytic Agents